Hemophilia

BioRx Introduces Smartphone App for Tracking Hemophilia Healthcare Information

BioRx Introduces Smartphone App for Tracking Hemophilia Healthcare Information

BioRx Introduces Smartphone App for Tracking Hemophilia Healthcare Information

 

BioRx Introduces Smartphone App for Tracking Hemophilia Healthcare Information

 

 

NBN Infusions delivers comprehensive services to patients of all ages, from pediatric to geriatric, providing a full range of care for Home Infusion Therapy. NBN Infusions on-site, licensed pharmacy can provide prescription medications, equipment, supplies and skilled nursing care needed for Home Infusion Therapy.

Home Infusion Therapy is a more convenient and cost-effective option than traditional inpatient therapy, with care administered in the comfortable surroundings of one’s own home. Home Infusion Therapy allows for a more active role in one’s own health care. It can also ease stress and anxiety that is sometimes associated with inpatient treatment, resulting in better patient outcomes.

 

The first hemophilia app developed by a specialty pharmacy

 

CINCINNATI–(BUSINESS WIRE)– BioRx, a national specialty pharmacy and infusion services provider, announced the launch of its industry’s first smartphone app designed for patients with hemophilia and related bleeding disorders. The app, called MyFactor, was developed and tested extensively by members of the hemophilia patient community. It was created to give patients and caregivers one place to easily monitor and manage their home treatment.

 

The first version of the app, to be released on the Apple Store next month, allows patients to electronically record bleeding episodes and treatments, and facilitates easy sharing of information with their healthcare team, including physicians, pharmacists, nurses and care coordinators. Further planned releases of the app, due in 2014, will allow customers to access their BioRx pharmacy records and track delivery of medications to their home.

 

“MyFactor is the first hemophilia app from a specialty pharmacy,” said Eric Hill, co-founder of BioRx. “This creates a unique platform for BioRx customers and staff to more efficiently communicate, exchange detailed treatment information, and helps both parties to anticipate and plan for future needs.”

 

Today, the vast majority of people with bleeding disorders receive homecare pharmacy and infusion services to help manage their day-to-day care. In moderate to severe cases, patients typically self-infuse and receive monthly shipments of their clotting factor medication and infusion supplies. Physician visits may not be frequent, but interaction with the pharmacy is routine. Keeping track of hemophilia bleeding episodes and treatments (as often as 3 or 4 times per week) can become a burden to patients and caregivers, especially over time; however, communicating these events is important to monitoring for potential joint damage from repeat bleeds, determining the need for dose adjustments, and diagnosing other issues that may impact health outcomes.

 

Bleeding disorder patients and caregivers can use a “wizard” style graphical interface on MyFactor to log details of treatments and bleeding episodes – including type, cause, location, and levels of pain and severity. A unique feature of the app gives users the option to scan the barcode of almost any brand of clotting factor in order to record its lot number. Maintaining a record of lot numbers is particularly important in the case of product recalls.

 

MyFactor can also generate historical reports in PDF and CSV formats at the touch of a button – customized by date range, keyword or event type. Reports from the app can easily be shared with others by selecting email addresses from the iPhone contact list, while access to the app can be password-protected on the device itself. Additionally, patients can use MyFactor to set up regular infusion reminders and alerts, add detailed notes, switch between multiple user accounts, and attach photos to show active bleeds, range of motion, or other information that may be useful to the healthcare team.

 

Originally Posted: HispanicBusiness.com  

 

 

Enhanced by Zemanta

European agency recommends Novo hemophilia drug for approval

 European agency recommends Novo hemophilia drug for approval

European agency recommends Novo hemophilia drug for approval

European agency recommends Novo hemophilia drug for approval

 

NBN Infusions delivers comprehensive services to patients of all ages, from pediatric to geriatric, providing a full range of care for Home Infusion Therapy. NBN Infusions on-site, licensed pharmacy can provide prescription medications, equipment, supplies and skilled nursing care needed for Home Infusion Therapy.

 

Home Infusion Therapy is a more convenient and cost-effective option than traditional inpatient therapy, with care administered in the comfortable surroundings of one’s own home. Home Infusion Therapy allows for a more active role in one’s own health care. It can also ease stress and anxiety that is sometimes associated with inpatient treatment, resulting in better patient outcomes.

 

COPENHAGEN (Reuters) – Danish insulin maker Novo Nordisk has received a recommendation for marketing approval from a European Medicines Agency (EMA) committee for its hemophilia treatment turoctocog alfa.

 

The company said on Friday the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the drug, also known as NovoEight, which belongs to a class of hemophilia drugs called factor 8.

 

“We are very happy to now have treatment in this mainstream hemophilia market, which we have never had before,” said Chief Science Officer Mads Krogsgaard Thomsen.

 

Thomsen said the total market for factor 8 hemophilia is worth 35-40 billion Danish crowns ($6.36 billion to $7.26 billion) in terms of sales.

 

He said the company expects to receive final marketing authorization from the European Commission in two to three months.

 

The company said in the statement it expects to launch the drug in Europe early next year.

 

NovoEight has also been filed for marketing authorization in the United States, Japan, Australia and Switzerland.

 

($1 = 5.5067 Danish crowns)

 

(Reporting by Mette Fraende and Shida Chayesteh; Editing by Elaine Hardcastle)

 

Originally posted by Yahoo News 

 

If you would like to know more about hemophilia contact NBN Infusions.

 

Enhanced by Zemanta